Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|October 20, 2015
Bodimetrics Performance Monitor Capabilities
Neil Friedman, COO at Bodimetrics, describes some of the key capabilities of the Bodimetrics Performance Monitor.
Advertisement
Neil Friedman, COO at Bodimetrics, describes some of the key capabilities of the Bodimetrics Performance Monitor.
This video was recorded at NACDS's Total Store Exposition in Denver in August 2015.
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Eight Humira biosimilars have been launched, but payer formularies and interchangeability rules decide what dispenses.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
4
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
5